Oncotarget

Researchers discuss new drugs for HER2+ breast cancer patients with brain metastasis, highlighting better survival and new therapeutic strategies targeting the HER2 protein. Ongoing clinical trials show promising intracranial responses with trastuzumab deruxtecan for different settings of CNS involvement.

Researchers discuss MET gene alterations in lung cancer, focusing on targetable changes like exon 14 skipping mutations and fusions. Capmatinib and Crizotinib show promise as treatments, but drug resistance remains a challenge. Various MET tyrosine kinase inhibitors are in development or under evaluation for potential combination therapies.

The podcast discusses the role of genetic variations in cancer development and treatment, focusing on predicting the molecular functions of cancer-associated genetic variants. It explores recent advances in identifying and characterizing these variants and proposes a framework for prediction based on genomic context and epigenetic marks. The podcast also delves into the interaction between MITF and MYC genes in melanocyte biology and cancer, and the use of computational models to predict TF binding sites and gene expression.

Amber J. Kiliti from Georgetown University Medical Center discusses how subpopulations of AIB1-expressing breast cancer cells enable invasion and metastasis. They explore the genetic and epigenetic events that drive tumor cell proliferation and the impact on tumor growth and invasion. The role of subclonal populations and the AIB1 splice isoform are also explored.

Researchers from Personalis, Inc. detail the validation of NeXT Dx, a genomic profiling assay for solid tumor cancers. The assay provides clinicians with information on cancer-related mutations, drug responses, and clinical trial options. Proprietary methods enhance variant calling accuracy and fusion detection, offering advanced sequencing technology for personalized treatment selection.

Research perspective discusses adopted neoplastic cells in tumors, where normal cells mimic neoplastic traits without genetic changes. Implications for cancer research and need for experimental studies are highlighted.

Dr. Mangesh A. Thorat discusses the multiclonality of ER expression in DCIS and its implications on personalized treatment outcomes. The podcast dives into the significance of clonal methodology in understanding ER expression in breast cancer.

The podcast delves into the evolving role of macrophages in promoting metastasis and tumor growth, focusing on their functions in lung colonies in a melanoma mouse model and impact on tissue integrity.

Researchers discuss the challenges in detecting and validating gene fusions in aggressive luminal breast cancer. They explore a neoplastic fusion transcript linked to aggressive clinical characteristics and propose the use of a MEK inhibitor for targeted therapy.

Exploring the impact of inhibiting glutamine metabolism on cancer cells and the tumor microenvironment, including targeting glutaminase, clinical studies on GLN dysregulation, and the connection with cancer-associated fibroblasts promoting cancer metastasis.